Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Collegium Pharmaceutical (NAS:COLL) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Collegium Pharmaceutical's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
27.20
/
49.02
=
0.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical Median PS Value Related Terms
Collegium Pharmaceutical Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COLL vs ETON, ALVO, PCRX: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.2961.
Collegium Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.349.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (COLL) has a Median PS Value of $49.02 as of Aug. 10, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Collegium Pharmaceutical and its competitors. According to the industry distribution chart, Collegium Pharmaceutical ranks #138 out of 548 companies in the Drug Manufacturers industry, placing it in the top 25.2%.
Is Collegium Pharmaceutical's Median PS Value too high?
Collegium Pharmaceutical's current Median PS Value is $49.02. The Drug Manufacturers industry median Median PS Value is 0.88. Collegium Pharmaceutical's value of $49.02 is 5470.5% above this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #138 out of 548 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Collegium Pharmaceutical has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Median PS Value compare to ETON and ALVO?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #138 out of 548 companies for Median PS Value. This puts Collegium Pharmaceutical in the upper half of its industry. The industry median Median PS Value is 0.88. Collegium Pharmaceutical's value of $49.02 is 5470.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.88, based on 548 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current Median PS Value of $49.02 is 5470.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Collegium Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current Median PS Value is $49.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (COLL) is currently considered Possible Value Trap. The stock's GF Value™ is $46.67, compared to a current price of $27.20 — trading 41.7% below its estimated fair value. The current Median PS Value is $49.02 and 5470.5% above the Drug Manufacturers industry median of 0.88. Collegium Pharmaceutical's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Collegium Pharmaceutical (COLL), the current Median PS Value is $49.02 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (COLL) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of $27.20 is trading 41.7% below its estimated GF Value™ of $46.67.
GuruFocus considers Collegium Pharmaceutical to be Possible Value Trap.
Key valuation signals for COLL:
Median PS Value: $49.02
GF Value™: $46.67 vs. price of $27.20 (41.7% below fair value)
Industry Position: 5470.5% above the Drug Manufacturers median (#138 of 548)
No single metric tells the full story. See the COLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
79GF Score
Get the complete analysis for COLL
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COLL has been successfully added to your 
